The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Radiation Research

• Publication date

  1998-02-01

• Fields of study

  Medicine, Physics, Chemistry

• Identifiers
  DOI 10.2307/3579925PMID 9457895
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2-a preliminary report

  2005cited by this paper
• Comments on ICRU report no. 49: stopping powers and ranges for protons and alpha particles.

  1999cited by this paper
• The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody.

  1996cited by this paper
• Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction

  1996cited by this paper
• Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates

  1996cited by this paper
• Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.

  1996cited by this paper
• Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.

  1996cited by this paper
• Targeted therapy using alpha emitters.

  1996cited by this paper
• Relationships between cell survival and specific energy spectra for therapeutic alpha-particle emitters.

  1996cited by this paper
• Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.

  1996cited by this paper
• Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.

  1994cited by this paper
• Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.

  1994cited by this paper
• Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

  1994cited by this paper
• Analysis of survival of C-18 cells after irradiation in suspension with chelated and ionic bismuth-212 using microdosimetry.

  1994cited by this paper
• The relationships between RBE and LET for different types of lethal damage in mammalian cells: biophysical and molecular mechanisms.

  1994cited by this paper
• Mouse/Human Chimeric Me1-14 Antibody: Genomic Cloning of the Variable Region Genes, Linkage to Human Constant Region Genes, Expression, and Characterization

  1994cited by this paper
• Effects of 210Po alpha particles on survival and preneoplastic transformation of primary rat tracheal epithelial cells irradiated while in suspension or in the intact tissue.

  1993cited by this paper
• A model of cell inactivation by alpha-particle internal emitters.

  1993cited by this paper
• Estimation of variance for AUC in animal studies.

  1993cited by this paper
• Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.

  1992cited by this paper
• Radiobiology of α Particles: III. Cell Inactivation by α-Particle Traversals of the Cell Nucleus

  1991cited by this paper
• Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus.

  1991cited by this paper
• Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

  1989cited by this paper
• Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.

  1988cited by this paper
• Specific chromosomal abnormalities in malignant human gliomas.

  1988cited by this paper
• Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves.

  1985cited by this paper

• Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment

  2025cites this paper
• Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials

  2024cites this paper
• Astatine-211 based radionuclide therapy: Current clinical trial landscape

  2023cites this paper
• Radiopharmaceuticals Based on Alpha Emitters: Preparation, Properties, and Application

  2018cites this paper
• Targeted and Nontargeted α-Particle Therapies.

  2018cites this paper
• 211At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatment.

  2017cites this paper
• Microarray Studies on 211At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Nonthyroid Tissues

  2017cites this paper
• Transcriptional response in normal mouse tissues after i.v. 211At administration - response related to absorbed dose, dose rate, and time

  2015cites this paper
• Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.

  2013cites this paper
• Production of [211At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle Therapy

  2013cites this paper
• Comparative Analysis of Transcriptional Gene Regulation Indicates Similar Physiologic Response in Mouse Tissues at Low Absorbed Doses from Intravenously Administered 211At

  2013cites this paper
• Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts

  2012cites this paper
• Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice.

  2012cites this paper
• Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma.

  2011cites this paper
• Alpha-particle microdosimetry.

  2011cites this paper
• Targeted Radiotherapy of Central Nervous System Malignancies

  2010cites this paper
• Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues.

  2010cites this paper
• Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. II. Application of the Microdosimetric Model to Experimental Results

  2009cites this paper
• Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. I. Presentation and Validation of a Microdosimetric Model

  2009cites this paper
• Peptide-targeted radionuclide therapy for melanoma.

  2008cites this paper
• mall-Scale Dosimetry : hallenges and Future Directions

  2008cites this paper
• Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.

  2008cites this paper
• Astatine Radiopharmaceuticals: Prospects and Problems.

  2008cites this paper
• Small-scale dosimetry: challenges and future directions.

  2008cites this paper
• NG2/HMP proteoglycan as a cancer therapeutic target.

  2007cites this paper
• Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

  2007cites this paper
• Implementation of a Microdosimetric Model for Radioimmunotherapeutic Alpha Emitters

  2007cites this paper
• Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

  2007cites this paper
• CANCER DRUG DISCOVERY AND DEVELOPMENT

  2007cites this paper
• Mechanismen der Zytotoxizität durch Alpha- Strahlung in humanen normalen und malignen hämatopoetischen Zellen

  2007cites this paper
• Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters

  2007cites this paper
• Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model

  2006cites this paper
• Intralesional targeted alpha therapy for metastatic melanoma

  2005cites this paper
• Melanoma therapy via peptide-targeted {alpha}-radiation.

  2005cites this paper
• Cancer radioimmunotherapy with alpha-emitting nuclides

  2005cites this paper
• Melanoma Therapy via Peptide-Targeted α-Radiation

  2005cites this paper
• Potential and pitfalls of therapy with alpha-particles.

  2005cites this paper
• Immunotherapy of Central Nervous System Tumors

  2005cites this paper
• Targeted α-Particle Therapy

  2005cites this paper
• Potential and Pitfalls of Therapy with α-Particles

  2005cites this paper
• Skeletal dosimetry models for alpha-particles for use in molecular radiotherapy

  2005cites this paper
• Simulation of Binary Methods for the Microdosimetric Analysis of Cell Survival after Alpha-Particle Irradiation: Ability to Distinguish between Different Models

  2004cites this paper
• Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides.

  2004cites this paper
• Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides

  2004cites this paper
• Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin.

  2004cites this paper
• Radioimmunotherapy with alpha-particle emitting radionuclides.

  2004cites this paper
• In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells

  2004cites this paper
• Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion.

  2004cites this paper
• Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2

  2003cites this paper
• Targeted alpha therapy of prostate cancer.

  2003cites this paper
• Progress in immunoconjugate cancer therapeutics.

  2003cites this paper
• Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.

  2003cites this paper
• Characterization of an Alpha-Particle Irradiator for Individual Cell Dosimetry Measurements

  2003cites this paper
• In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen

  2002cites this paper
• NG2 precursor cells in neoplasia: Functional, histogenesis and therapeutic implications for malignant brain tumours

  2002cites this paper
• In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes.

  2002cites this paper
• Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer.

  2002cites this paper
• In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer

  2001cites this paper
• High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.

  2001cites this paper
• Similarities and differences between free 211At and 125I- transport in porcine thyroid epithelial cells cultured in bicameral chambers.

  2001cites this paper
• High-Level Production of α-Particle–Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use

  2001cites this paper
• In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.

  2001cites this paper
• Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.

  2001cites this paper
• Exposure of human osteosarcoma and bone marrow cells to tumour-targeted α-particles and γ-irradiation: analysis of cell survival and microdosimetry

  2000cites this paper
• Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.

  2000cites this paper
• Tumor Control Probability Model for Alpha-Particle-Emitting Radionuclides

  2000cites this paper
• Nuklearmedizinische Therapie - Aufbruch in neue Dimensionen?

  2000cites this paper
• Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: Effect on clonogenicity in both two-and three-dimensional models

  2000cites this paper
• Radiation effects in spheroids of cells exposed to alpha emitters

  2000cites this paper
• [Nuclear medicine--therapeutic advances into new dimensions?].

  2000cites this paper
• Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.

  2000cites this paper
• Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.

  1999cites this paper
• The survival of monolayers of cells growing in clusters irradiated by 211At appended to the cell surfaces.

  1999cites this paper
• Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells.

  1999cites this paper
• LIMITED RIGHTS LEGEND Award Number : DAMD 1799-1-9383 Organization : Saint George Hospital Cancer Care

  year unknowncites this paper